ArticleLife (Basel, Switzerland)2021
Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease.
Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Salivary Alterations of Myeloperoxidase in Patients with Systemic Diseases: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Elevated periodontal disease risk in ulcerative colitis patients: evidence from a comparative case-control study.Odontology · 2026Article
- Salivary Biomarkers in Crohn's Disease and Ulcerative Colitis: A Scoping Review and Evidence Map.International journal of molecular sciences · 2025Article
- Saliva as a Diagnostic Tool for Systemic Diseases-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Shared immune-inflammatory mechanisms between ulcerative colitis and periodontitis: a multi-omics analysis.Frontiers in immunology · 2025Article
- Salivary Immunoglobulin a Alterations in Health and Disease: A Bibliometric Analysis of Diagnostic Trends from 2009 to 2024.Antibodies (Basel, Switzerland) · 2024Article
- Unravelling the Oral-Gut Axis: Interconnection Between Periodontitis and Inflammatory Bowel Disease, Current Challenges, and Future Perspective.Journal of Crohn's & colitis · 2024Review
- The Effect of Biological Treatment on Stress Parameters Determined in Saliva in Patients with Severe Psoriasis.Medicina (Kaunas, Lithuania) · 2023Article
- Emerging Role of Neutrophil Extracellular Traps in Gastrointestinal Tumors: A Narrative Review.International journal of molecular sciences · 2022Review
- Review
- Differential diagnosis of ulcerative colitis with increased diarrhea; collagenous colitis or irritable bowel syndrome? A case report.The Journal of international medical research · 2022Article
- Pathogenic associations between oral and gastrointestinal diseases.Trends in molecular medicine · 2022Review
- Oral Health in Patients with Inflammatory Bowel Diseases Qualified for Biologic Treatment.International journal of environmental research and public health · 2022Article
- Immunoglobulin Disorders and the Oral Cavity: A Narrative Review.Journal of clinical medicine · 2022Review
- Oral manifestations serve as potential signs of ulcerative colitis: A review.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously observed that inflammatory bowel disease (IBD) may compromise oral host defense, as assessed by decreased salivary levels of immunoglobulin A (IgA) and myeloperoxidase (MPO). Biologic therapy with inhibitors of cytokines or adhesion molecules is increasingly used for patients with IBD. Little is known, however, about how this treatment modality affects the release and properties of saliva. Here, we aimed to determine how biologic therapy in patients who had not responded to previous standard treatment with conventional drugs affected the salivary concentration of IgA and MPO. To this end, unstimulated whole mixed saliva was collected before treatment or after 10-12 weeks of therapy from 27 patients with Crohn's disease (CD) and 24 patients with ulcerative colitis (UC). After the induction phase of therapy with biologics, salivary levels of IgA and MPO increased significantly in UC, but not in CD patients. These increases were approximately 8-fold and 6-fold, for IgA and MPO, respectively. Moreover, these effects occurred in UC patients who responded successfully to therapy, but not in those who failed to improve. Furthermore, the relative increases in salivary IgA and MPO correlated with the relative decrease in UC severity, as assessed by the Mayo scale. These data indicate that the successful therapy with biologics in UC patients results also in improved oral host defense. However, it remains to be determined why such an effect does not occur during therapy for CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.